BioSpace News Archive

Tenax Therapeutics, Inc. (Nasdaq: TENX), today announced that two presentations will be made at the upcoming American College of Cardiology (ACC) Scientific Sessions featuring the Company’s lead drug candidates, imatinib and levosimendan.

SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property, today announced its operating and financial results for the fourth quarter and year ended December 31, 2021.

Micron Solutions, Inc. (OTCQB: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, Inc., producing highly-engineered, innovative components requiring precision machining and injection molding, announced financial results for its fourth quarter and fiscal year ended December 31, 2021.

According to a new preliminary study, children and teens with Tourette syndrome who are treated with an experimental drug called ecopipam may have improved scores on tests of tic severity three months later.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) meeting to review the Company’s New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO; also known as ursodoxicoltaurine]) for the treatment of amyotrophic lateral sclerosis (ALS).

Telix Pharmaceuticals Limited announces that Tiffany Olson has been appointed to the Board, as a U.S.-based independent, Non-Executive Director.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the full year ended December 31, 2021.

Everest Medicines (HKEX 1952.HK), announced today that it has submitted a New Drug Application (NDA) to the Department of Health, the Hong Kong Special Administrative Region, China for sacituzumab govitecan.

CStone Pharmaceuticals (“CStone”, HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the first patient has been enrolled in the U.S. in the Phase 1 clinical trial for CS5001.